Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Kodie NoyBiology of Viral Emerging Infections Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Rachel LegendreBioinformatics and Biostatistics Hub, Institut Pasteur, Université Paris Cité, Paris, France.
Séverine CrozeProfileXpert, Faculté de Pharmacie de Lyon, Université de Claude Bernard Lyon 1, UMS 3453 CNRS - US7 INSERM, Lyon, France.
Valérie NajburgInstitut Pasteur-Oncovita Joint Laboratory, Université Paris Cité, Institut Pasteur, Paris, France.
Romane FernandezBiology of Viral Emerging Infections Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Julie LuciforaCentre International de Recherche en Infectiologie (CIRI), Université de Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS de Lyon, Lyon, France.
Joel LachuerProfileXpert, Faculté de Pharmacie de Lyon, Université de Claude Bernard Lyon 1, UMS 3453 CNRS - US7 INSERM, Lyon, France.
Sylvain BaizeBiology of Viral Emerging Infections Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-3234-7477
Anastassia V KomarovaInstitut Pasteur-Oncovita Joint Laboratory, Université Paris Cité, Institut Pasteur, Paris, France.ORCID 0000-0002-9998-8447
Mathieu MateoBiology of Viral Emerging Infections Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0001-7941-0245
Funding
Agence Nationale de la Recherche ANR 21 CE18-0004-01Fondation Innovations en Infectiologie AP2018-13
6 · The paper itself
Abstract
All viruses of the genus
Indexed as
Arenaviruses, Old WorldDEAD Box Protein 58ExoribonucleasesLassa virusRNA, ViralAdaptor Proteins, Signal TransducingAnimalsHEK293 CellsHumansInterferon-Induced Helicase, IFIH1InterferonsNucleoproteinsReceptors, ImmunologicRNA, Double-StrandedVirus ReplicationAdaptor Proteins, Signal TransducingDEAD Box Protein 58ExoribonucleasesIFIH1 protein, humanInterferon-Induced Helicase, IFIH1InterferonsMAVS protein, humanNucleoproteinsReceptors, ImmunologicRIGI protein, humanRNA, Double-StrandedRNA, Viralarenavirusesinterferon responseRIG-I-like receptorsviral RNA
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Lassa and Mopeia viruses produce different RIG-I-activating RNA in the absence of a functional viral exoribonuclease domain. · full record | Socratic